**Michigan Medicine Evusheld Administration Criteria**

Evusheld (tixagevimab-cilgavimab) is a preventive monoclonal antibody for COVID-19. Due to the emergence of resistant COVID-19 variants, Evusheld should not be routinely administered. Patients who have received Evusheld should be notified that limited to no prophylactic efficacy is expected and to continue to adhere to preventive precautions, including up-to-date vaccination (including the bivalent booster), masking, and social distancing as warranted. Patients inquiring about Evusheld should be informed that while it is still available for administration, no benefit is expected.

**Administration:**
- Evusheld is administered as two separate 3.0-mL (300 mg/300 mg) gluteal intramuscular injections
- Patients should receive repeat dosing **every 6 months**
- Platelet count >30,000 cells/mm$^3$ required
- Patients must be consented for administration of the EUA product (documented with .azcovidmab; only required for first dose)
- Patients must be provided with the Patient EUA fact sheet (available with .azcovidmabfact or here: https://www.fda.gov/media/154702/download; only required for first dose)
- Patients must be medically observed for 1 hour after administration

**Process for ordering Evusheld:**
1) Identify appropriate patients
   - Should only be offered to patients who specifically request Evusheld after being made aware that no benefit is expected

2) Consent patient – only required for first dose
   - Discuss with patient and obtain verbal consent (nurses, physicians, and pharmacists may provide consent)
   - Provide EUA patient caregiver / factsheet: https://www.fda.gov/media/154702/download
   - Document consent using .azcovidmab

3) Schedule patient
   - Option 1: administer in clinic if RN available to provide gluteal IM injections
     - May add product to clinic formulary and requisition using normal process
     - Follow usual process for ordering clinic-administered medications
   - Option 2: send for central scheduling in Northville or Brighton injection clinics
     - Enter order for “Evusheld referral”
     - May be a significant delay in administration due to limited capacity

---

**Revision History:**
- 1/27/22: Revised criteria for use
- 2/17/22: Clarified vaccine recommendations
- 3/8/22: Revised process for administration
- 4/4/22: Revising dosing
- 11/4/22: Revised process for administration

The recommendations in this guide are meant to serve as treatment guidelines for use at Michigan Medicine facilities. If you are an individual experiencing a medical emergency, call 911 immediately. These guidelines should not replace a provider’s professional medical advice based on clinical judgment, or be used in lieu of an Infectious Diseases consultation when necessary. As a result of ongoing research, practice guidelines may from time to time change. The authors of these guidelines have made all attempts to ensure the accuracy based on current information, however, due to ongoing research, users of these guidelines are strongly encouraged to confirm the information contained within them through an independent source.

If obtained from a source other than med.umich.edu/asp, please visit the webpage for the most up-to-date document.